Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa is under clinical development by Holostem Terapie Avanzate and currently in Phase II for Epidermolysis Bullosa. According to GlobalData, Phase II drugs for Epidermolysis Bullosa have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa overview
Gene therapy is under development for the treatment of junctional epidermolysis bullosa (JEB). It consists of autologous cultured epidermal grafts containing epidermal stem cells genetically modified with the aid of a retroviral vector carrying LAMB-3 cDNA. It is administered through cutaneous route.
For a complete picture of Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa’s drug-specific PTSR and LoA scores, buy the report here.